Sub-Cutaneous Insulin in Hyperglycaemic Emergencies
Withdrawn
The Royal Bournemouth Hospital
N/A
1969-12-31
Hyperglycaemic emergencies are associated with significant mortality (mortality in Diabetic
Ketoacidosis 0.65 - 3.3% and in HyperOsmolar Non-Ketotic Coma 12 -17%). To reduce morbidity
and mortality, prompt intervention and coma and close monitoring are essential. The study is
designed to investigate whether a simple intervention with a long acting insulin can improve
resolution of acidosis and hyperglycaemia, prevent recurrence of ketoacidosis and shorten
hospital stay.
Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
Completed
Merck Sharp & Dohme Corp.
Early Phase 1
2008-04-01
This study will investigate the effects of sitagliptin, a medicine commonly used to treat
type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure
which is not due to heart attacks. We hope to determine whether improving the heart's ability
to use glucose in the blood may help improve the function of the heart as well. If so, this
may suggest that even people who do not have frank diabetes but who do have heart failure may
benefit from using this medication.
This study will also investigate the effect of sitagliptin on the body's use of sugar, and of
the effect of sitagliptin on blood flow to the heart.
Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
Completed
Stanford University
Early Phase 1
2008-04-01
This study will investigate the effects of sitagliptin, a medicine commonly used to treat
type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure
which is not due to heart attacks. We hope to determine whether improving the heart's ability
to use glucose in the blood may help improve the function of the heart as well. If so, this
may suggest that even people who do not have frank diabetes but who do have heart failure may
benefit from using this medication.
This study will also investigate the effect of sitagliptin on the body's use of sugar, and of
the effect of sitagliptin on blood flow to the heart.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.